Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Nevada Business Herald.
Press releases published on August 12, 2025
DeFi Development Corp. Announces Second Quarter 2025 Earnings
BOCA RATON, FL, Aug. 12, 2025 (GLOBE NEWSWIRE) -- https://www.youtube.com/@DeFiDevCorp DeFi Development Corp. (Nasdaq: DFDV) (the “Company” or “DeFi Dev Corp.”), the first US public company with a treasury strategy built to accumulate and compound Solana …
SELLAS Life Sciences Reports Second Quarter 2025 Financial Results and Provides Corporate Update
- Positive IDMC Recommendation to Continue Pivotal Phase 3 REGAL Trial of Galinpepimut-S (GPS) in AML Without Modification; Final Analysis Anticipated by Year-end 2025 – - Reported Positive Phase 2 Results of SLS009 in Relapsed/Refractory (r/r) Acute …
Fractyl Health Announces Second Quarter 2025 Financial Results and Business Updates
Randomized 3-month REMAIN-1 Midpoint Cohort data expected in September 2025 Positive 3-month REVEAL-1 Cohort data showed single Revita® procedure sustained weight loss after GLP-1 discontinuation; incremental 6-month open-label data expected in Q4 2025 Top …
NeuroPace Reports Second Quarter 2025 Financial Results and Increases 2025 Revenue Guidance
-- Reported record quarterly revenue of $23.5 million in Q2 2025-- -- Increased full-year 2025 revenue guidance to between $94 million and $98 million and gross margin guidance to between 75% and 76%-- -- Remain on track to submit NAUTILUS data to FDA for …
Slide Reports Second Quarter 2025 Results
- Gross Premiums Written Increased 25.0% Year-over-Year to $435.4 Million - - Net Income Grew 30.5% Year-over-Year to $70.1 Million; $0.56 Diluted Earnings Per Share - - Combined Ratio Improved 250 Basis Points Year-over-Year to 67.4% - - Completed Initial …
Alico, Inc. Announces Financial Results for the Third Quarter Ended June 30, 2025
Company Completes Final Major Citrus Harvest as Strategic Transformation to Diversified Land Company Continues Company Reports $9.3 Million in Third Quarter Asset Sales; Exceeding its Land Sales Target Crop Insurance Recovery of $16.0 Million Contributes …
Iridex Reports Second Quarter 2025 Financial Results
MOUNTAIN VIEW, Calif., Aug. 12, 2025 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and procedure probes for the treatment of glaucoma and retinal …
Mobile Infrastructure Reports Second Quarter 2025 Financial Results
--Higher Contract Parking Volumes Reflect Positive Secular Growth Trends-- --Advancing Non-Core Asset Divestiture Strategy-- --Conference Call Will be Held Today at 4:30 PM ET-- CINCINNATI, Aug. 12, 2025 (GLOBE NEWSWIRE) -- Mobile Infrastructure …
WEBTOON Entertainment Inc. Reports Second Quarter 2025 Financial Results
Delivered Revenue and Adjusted EBITDA above the top end of Guidance Ranges Second Quarter Revenue Growth of 8.5%; Revenue Growth on a Constant Currency Basis of 5.5% Net Loss of $3.9 Million; Adjusted EBITDA of $9.7 Million Strong Balance Sheet With Cash …
Inspirato Reports Q2 Financial and Operating Results
DENVER, Aug. 12, 2025 (GLOBE NEWSWIRE) -- Inspirato Incorporated (“Inspirato” or the “Company”) (Nasdaq: ISPO), the premier luxury vacation club and property technology company, today reported results for the second quarter (“Q2 2025”) ended June 30, 2025. …
Beyond Air® Reports Fiscal First Quarter 2026 Financial Results and Provides Corporate Update
Increased revenues by 157% to $1.8 million, compared with $0.7 million for the fiscal quarter ended June 30, 2024 Awarded a national group purchasing agreement for therapeutic gases by Premier, Inc., which has more than 4,350 member hospitals and health …
Annovis Provides Corporate Updates and Reports Second Quarter 2025 Financial Results
MALVERN, Pa., Aug. 12, 2025 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer's disease (AD) and …
ORIC® Pharmaceuticals Reports Second Quarter 2025 Financial Results and Operational Updates
Reported potentially best-in-class clinical efficacy and safety data from ongoing Phase 1b trial of ORIC-944 in combination with AR inhibitors for the treatment of patients with mCRPC Strengthened cash position with $244 million gross proceeds from top- …
Generation Bio Announces New Data for Its Novel ctLNP Delivery System and Early T Cell Programs and Reports Second Quarter 2025 Financial Results
• New data confirm highly selective profile of cell-targeted lipid nanoparticle (ctLNP) and first-ever siRNA delivery to T cells in non-human primates • Lead siRNA candidates show potent knockdown of LAT1 and VAV1, targets potentially relevant to T cell- …
Caribou Biosciences Reports Second Quarter 2025 Financial Results and Provides Business Update
-- Two robust clinical datasets from CB-010 and CB-011 expected to be disclosed in H2 2025 -- -- $184 million in cash, cash equivalents, and marketable securities expected to fund the Company’s current operating plan into H2 2027 -- BERKELEY, Calif., Aug. …
Mineralys Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update
– Presented and published the positive results from both the Launch-HTN and Advance-HTN pivotal trials at scientific meetings and in JAMA and NEJM – – Pre-NDA meeting scheduled to take place in 4Q 2025 – – Explore-CKD Phase 2 trial successfully achieved …
Fold Holdings, Inc. (NASDAQ: FLD) Announces Second Quarter 2025 Results
Revenue: $8.2 million, 59% YoY increase Net Income: $13.4 million New accounts up over 233% YoY and transaction volumes up 124% YoY Successfully secured $250 million equity purchase facility 1 Bitcoin Investment Treasury Holdings: 1,492 BTC PHOENIX, Aug. …
Pharvaris Reports Second Quarter 2025 Financial Results and Provides Business Update
Topline results for RAPIDe-3, a pivotal Phase 3 study of deucrictibant for the on-demand treatment of HAE attacks, expected in 4Q2025 Enrollment continues in CHAPTER-3, a pivotal Phase 3 study of deucrictibant for prophylaxis of HAE attacks; topline …
NEXGEL Reports Second Quarter 2025 Financial Results
Second quarter 2025 revenue totaled $2.88 million, an increase of 100.3% as compared to $1.44 million for the same period year-over-year Gross Profit for the quarter was 43.6%, compared to 20.3% for the same period in 2024 Company is reiterating revenue …